search
Back to results

Dietary Carbohydrate and Internal Body Fat (CARBFUNC)

Primary Purpose

Adiposity

Status
Completed
Phase
Not Applicable
Locations
Norway
Study Type
Interventional
Intervention
Acellular carbohydrate diet
Cellular carbohydrate diet
Low-carbohydrate high-fat diet
Sponsored by
Haukeland University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Adiposity focused on measuring Body composition, Internal body fat, Dietary pattern, Dietary carbohydrate

Eligibility Criteria

20 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Body-mass index (BMI) equal to or above 30 kg/m2 and/or waist circumference equal to or above 102 cm for men and 88 cm for women
  • Weight stable during the last 2 months before start of the study (less than 5 % change in body weight up or down)
  • No known diabetes or consumption of diabetes medication
  • Desire to follow a specified dietary pattern using specific recipes throughout the time of the study period
  • Ability to periodically record food intake using a specially designed app for the study

Exclusion Criteria:

  • Use of statins and/or diabetes medication
  • Recent surgical or antibiotics treatment during the last 2 months before start of the study
  • Chronic inflammatory bowel disease
  • Serious disease
  • Smoking
  • Pregnancy or breast feeding
  • Alcohol consumption during the study of more than 2 alcohol units per day (1 unit = 15 ml (12.8 g) pure alcohol)

Sites / Locations

  • Forskningsenhet for helseundersøkelser (research unit for clinical trials), Department of Clinical Science, University of Bergen

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Experimental

Experimental

Arm Label

Acellular carbohydrate diet

Cellular carbohydrate diet

Low-carbohydrate high-fat diet

Arm Description

Prescribed dietary pattern. Carbohydrates from acellular sources, e.g., refined flour/bakery products, at least 500 grams of fruits/vegetables per day, and a macronutrient composition within typical nutritional recommendations for the general population.

Prescribed dietary pattern. Carbohydrates from cellular sources, e.g., root vegetables, fruits, whole-grain rice, non-flour grain products, at least 500 grams of fruits/vegetables per day, and a macronutrient composition within typical nutritional recommendations for the general population similar to the acellular carbohydrate diet.

Prescribed dietary pattern. Energy largely from fat, cellular carbohydrate sources, and otherwise similar food types as in the acellular/cellular carbohydrate diets including at least 500 grams of fruits/vegetables per day.

Outcomes

Primary Outcome Measures

Change in internal body fat
Visceral fat mass (cm3) measured by computed tomography (CT) imaging

Secondary Outcome Measures

Change in postprandial insulin
Circulating insulin concentrations measured before and 2 hours after intake of a standardized mixed meal
Change in postprandial C-peptide
Circulating C-peptide concentrations measured before and 2 hours after intake of a standardized mixed meal
Change in postprandial triacylglycerol
Triacylglycerol concentrations measured before and 4 hours after intake of a mixed meal
Change in postprandial area under the curve (AUC) glucose
Circulating glucose measured before and after 30, 60, 90, 120 and 240 minutes after intake of a standardized mixed meal
Change in postprandial non-esterified fatty acids
Circulating non-esterified fatty acid concentrations before and after 60, 120 and 240 minutes after intake of a standardized mixed meal
Change in fecal microbiome composition
Microbiome composition measured by 16S sequencing
Change in liver density
Calculated as liver/spleen attenuation index (Hounsfield units) based on quantification by computed tomography (CT) imaging
Change in pericardial fat mass
Pericardial fat mass (cm3) measured by computed tomography (CT) imaging
Change in abdominal subcutaneous fat mass
Abdominal subcutaneous fat mass (cm3) measured by computed tomography (CT) imaging
Change in coronary artery calcification (CAC)
CAC score calculated based on computed tomography (CT) imaging
Change in waist circumference
Waist circumference (cm) measured by a measuring tape
Change in body-mass index
Body-mass index measured as body weight (kg) divided by height (m) squared
Change in fasting insulin
Circulating fasting insulin concentrations
Change in fasting C-peptide
Circulating fasting C-peptide concentrations
Change in fasting TAG
Circulating fasting triacylglycerol concentrations
Change in fasting HDL cholesterol
Circulating fasting high-density lipoprotein cholesterol (HDL-C)
Change in TAG/HDL-C ratio
The ratio of circulating fasting triacylglycerol (TAG) and high-density lipoprotein cholesterol (HDL-C)
Change in fasting LDL cholesterol
Circulating fasting low-density lipoprotein cholesterol (LDL-C)
Change in apolipoprotein profile
Circulating fasting apolipoprotein profile measured by multiplex ELISA
Change in circulating and urine metabolites associated with one-carbon metabolism
Circulating metabolites in the serine, glycine and histidine pathways measured in the fasted state by GC-MS/MS
Change in total fat mass
Total fat mass measured by bioimpedance analysis (BIA)
Change in lean mass
Lean mass will be measured by bioimpedance analysis (BIA)
Change in appetite/fullness
Subjective appetite and fullness assessed and quantified by the VAS questionnaire
Change in gastrointestinal symptoms by the Roma III questionnaire
Gastrointestinal health will be surveyed and quantified by a questionnaire (Rome III Diagnostic Criteria for Irritable Bowel Syndrome (IBS)). The questionnaire surveys criteria for diagnosis of IBS within a 12-week period. The criteria for IBS are based on recurrent abdominal pain or discomfort, 3 days per month in the last 3 months (12 weeks), associated with ≥2 of the following criteria: 1.Improvement with defecation; 2. Onset associated with a change in stool frequency; 3. Onset associated with a change in stool form (appearance). The criteria are fulfilled with symptoms onset 6 months prior to diagnosis.
Change in gastrointestinal symptoms by the IBS-SSS questionnaire
Gastrointestinal health will be surveyed by the IBS-SSS questionnaire. Scores on the IBS-SSS range from 0 to 500 with higher scores indicating more severe symptoms. Subjects can be categorized as having mild (75-175), moderate (175-300), or severe (>300) IBS. A decrease of 50 points is associated with a clinically meaningful improvement. Each question on the VAS ranges from 0-100mm, where higher score indicates more severe symptoms. The categorization based on scores (total possible score = 500) are as follows: 0-75 = not IBS 75-175= mild IBS 175-300 = moderate IBS 300-500 = severe IBS
Change in fatigue
The Fatigue Impact Scale will be used to compute a total score for fatigue by summing up the scores for subclasses as follows: cognitive functioning (10 items, subscale range: 0-40), physical functioning (10 items, subscale range: 0-40), and psychosocial functioning (20 items, subscale range: 0-80). The statements are ranged on a five-level scale (0 = no problem to 4 = extreme problems), giving a maximum total FIS score of 160 (total scale range: 0-160) where low scores indicate less fatigue-related issues.
Change in perception of health / quality of life
Obesity-specific quality of life is measured with "Patient-Reported Outcomes in Obesity" (PROS), which consists of 8 items tapping how different life domains are affected by obesity. PROS have one overall score, ranging from 0 (optimal) to 3 (poorest). Generic health-related quality of life is measured with RAND-36, which consists of dimensions ranging from 0 (poorest) to 100 (optimal). There are 8 subscales; physical functioning, physical role functioning, bodily pain, general health, vitality, social functioning, emotional role functioning and mental health. In addition, RAND-36 also have 2 summary scores: the physical component summary (PCS) (tapping from physical functioning, physical role functioning, bodily pain and general health) and mental component summary (MCS) (tapping from vitality, social functioning, emotional role functioning and mental health).
Change in quality of life related to gastrointestinal symptoms
The SF-NDI (Short-Form Nepean Dyspepsia Index (SF-NDI)) questionnaire will be used to assess quality of life / psychological wellbeing related to gastrointestinal symptoms. The 10-item SF-NDI was constructed and validated in patients with functional gastrointestinal disorders for measuring health-related quality of life. The 10-item short form includes five subscales: tension, interference with daily activities, eating/drinking, knowledge/control, and work/study, and each subscale contains two items. The items were measured by a 5-point graded Likert scale from 1 to 5. A total sum score for quality of life and a sum score for each of the five subscales were calculated by adding up scores for each item (range of total quality of life, 10-50; range of each subscale, 2-10). Higher scores indicate worse functioning or symptoms.

Full Information

First Posted
August 23, 2017
Last Updated
April 23, 2021
Sponsor
Haukeland University Hospital
Collaborators
University of Bergen
search

1. Study Identification

Unique Protocol Identification Number
NCT03401970
Brief Title
Dietary Carbohydrate and Internal Body Fat
Acronym
CARBFUNC
Official Title
Dietary Carbohydrate and Internal Body Fat Mass in Women and Men With Obesity
Study Type
Interventional

2. Study Status

Record Verification Date
April 2021
Overall Recruitment Status
Completed
Study Start Date
January 3, 2018 (Actual)
Primary Completion Date
May 20, 2020 (Actual)
Study Completion Date
March 24, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Haukeland University Hospital
Collaborators
University of Bergen

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a 2-year randomized controlled trial to test the effect of dietary carbohydrates, both quality and quantity, on changes in internal body fat mass. Up to 250 women and men with obesity are recruited in Bergen, Norway, and randomized to one of the following normo- and isocaloric dietary patterns (same amount of protein, polyunsaturated fatty acids and moderate energy, 2,000 - 2,500 kcal per day): 1) a low-fat high-carbohydrate diet primarily with refined (e.g., flour-based) carbohydrate sources, 2) a low-fat high-carbohydrate diet based on minimally refined (e.g., cellular) carbohydrate sources, and 3) a very-high-fat low-carbohydrate diet.
Detailed Description
Obesity, and high internal fat storage in particular, represents a tremendous and increasing health challenge across the world, and is linked to the recent introduction and globalization of an ultra-processed food supply largely based on refined carbohydrates. However, more high-quality studies are needed to directly assess the role of carbohydrate quality in abdominal adiposity. We also need studies with greater long-term adherence to prescribed food profiles, which may be achievied with the help of new electronic tools such as meal planning applications. The participants select and plan all meals among a list of carefully designed options, using an application/recipe booklet developed for the study. Each recipe/meal/snack is designed to fully comply with the overall macronutrient- and dietary profile for the respective groups. We will further instruct the participants to record their meal choices during three days every 14 days, and to record all deviations throughout the intervention. Enrolled participants are invited to study visits at baseline and after 3, 6, 9, 12 and 24 months. At all or some of these time points, the participants provide biological samples (blood, urine and feces, and for some, adipose and/or muscle tissue) and undergo phenotyping, e.g., measurement of body weight and fat mass by bioelectrical impedance analysis and low-radiation CT imaging, and a standardized meal test with blood sample collection up to 4 hours postprandially. In addition, participants will be asked to fill out a collection of questionnaires that assess quality of life, motivation, fatigue, gastrointestinal health, appetite and physical activity. We ask the participants to maintain the same level of physical activity throughout the study. The primary outcome measure is change in internal body fat mass (visceral adipose tissue) measured by CT imaging. Secondary outcome measures include change in 2-hour postprandial serum concentrations of insulin, change in 4-hour postprandial serum concentrations of triacylglycerols, and change in fecal microbiota composition measured by 16S sequencing.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Adiposity
Keywords
Body composition, Internal body fat, Dietary pattern, Dietary carbohydrate

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
150 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Acellular carbohydrate diet
Arm Type
Active Comparator
Arm Description
Prescribed dietary pattern. Carbohydrates from acellular sources, e.g., refined flour/bakery products, at least 500 grams of fruits/vegetables per day, and a macronutrient composition within typical nutritional recommendations for the general population.
Arm Title
Cellular carbohydrate diet
Arm Type
Experimental
Arm Description
Prescribed dietary pattern. Carbohydrates from cellular sources, e.g., root vegetables, fruits, whole-grain rice, non-flour grain products, at least 500 grams of fruits/vegetables per day, and a macronutrient composition within typical nutritional recommendations for the general population similar to the acellular carbohydrate diet.
Arm Title
Low-carbohydrate high-fat diet
Arm Type
Experimental
Arm Description
Prescribed dietary pattern. Energy largely from fat, cellular carbohydrate sources, and otherwise similar food types as in the acellular/cellular carbohydrate diets including at least 500 grams of fruits/vegetables per day.
Intervention Type
Behavioral
Intervention Name(s)
Acellular carbohydrate diet
Intervention Description
Participants will be asked to consume 2,000 - 2,500 kcals, thereof 45 energy percent (E%) carbohydrate (up to 5 E% added sugar), 30 E% fat (10-12 E% saturated fatty acids and 7-10 E% polyunsaturated fatty acids) and 17 E% protein. They will use an original online/smartphone application that provides choices of meals/food combinations/recipes corresponding to their prescribed macronutrient profile and dietary pattern. Participants are asked to complete 3-day dietary records every 14 days throughout the study, and to report any deviations from the planned interventions.
Intervention Type
Behavioral
Intervention Name(s)
Cellular carbohydrate diet
Intervention Description
Participants will be asked to consume 2,000 - 2,500 kcals, thereof 45 energy percent (E%) carbohydrate (up to 1 E% added sugar), 38 E% fat (10-12 E% saturated fatty acids and 7-10 E% polyunsaturated fatty acids) and 17 E% protein. They will use an original online/smartphone application that provides choices of meals/food combinations/recipes corresponding to their prescribed macronutrient profile and dietary pattern. Participants are asked to complete 3-day dietary records every 14 days throughout the study, and to report any deviations from the planned interventions.
Intervention Type
Behavioral
Intervention Name(s)
Low-carbohydrate high-fat diet
Intervention Description
Participants will be asked to consume 2,000 - 2,500 kcals, thereof 10 energy percent (E%) carbohydrate (up to 1 E% added sugar), 73 E% fat (30 E% saturated fatty acids and 7-10 E% polyunsaturated fatty acids) and 17 E% protein. They will use an original online/smartphone application that provides choices of meals/food combinations/recipes corresponding to their prescribed macronutrient profile and dietary pattern. Participants are asked to complete 3-day dietary records every 14 days throughout the study, and to report any deviations from the planned interventions.
Primary Outcome Measure Information:
Title
Change in internal body fat
Description
Visceral fat mass (cm3) measured by computed tomography (CT) imaging
Time Frame
Baseline and 6, 12 and 24 months
Secondary Outcome Measure Information:
Title
Change in postprandial insulin
Description
Circulating insulin concentrations measured before and 2 hours after intake of a standardized mixed meal
Time Frame
Baseline and 3, 6, 9, 12 and 24 months
Title
Change in postprandial C-peptide
Description
Circulating C-peptide concentrations measured before and 2 hours after intake of a standardized mixed meal
Time Frame
Baseline and 3, 6, 9, 12 and 24 months
Title
Change in postprandial triacylglycerol
Description
Triacylglycerol concentrations measured before and 4 hours after intake of a mixed meal
Time Frame
Baseline and 3, 6, 9, 12 and 24 months
Title
Change in postprandial area under the curve (AUC) glucose
Description
Circulating glucose measured before and after 30, 60, 90, 120 and 240 minutes after intake of a standardized mixed meal
Time Frame
Baseline and 3, 6, 9, 12 and 24 months
Title
Change in postprandial non-esterified fatty acids
Description
Circulating non-esterified fatty acid concentrations before and after 60, 120 and 240 minutes after intake of a standardized mixed meal
Time Frame
Baseline and 3, 6, 9, 12 and 24 months
Title
Change in fecal microbiome composition
Description
Microbiome composition measured by 16S sequencing
Time Frame
Baseline and 3, 6, 9, 12 and 24 months
Title
Change in liver density
Description
Calculated as liver/spleen attenuation index (Hounsfield units) based on quantification by computed tomography (CT) imaging
Time Frame
Baseline and 6, 12 and 24 months
Title
Change in pericardial fat mass
Description
Pericardial fat mass (cm3) measured by computed tomography (CT) imaging
Time Frame
Baseline and 6, 12 and 24 months
Title
Change in abdominal subcutaneous fat mass
Description
Abdominal subcutaneous fat mass (cm3) measured by computed tomography (CT) imaging
Time Frame
Baseline and 6, 12 and 24 months
Title
Change in coronary artery calcification (CAC)
Description
CAC score calculated based on computed tomography (CT) imaging
Time Frame
Baseline and 6, 12 and 24 months
Title
Change in waist circumference
Description
Waist circumference (cm) measured by a measuring tape
Time Frame
Baseline and 3, 6, 9, 12 and 24 months
Title
Change in body-mass index
Description
Body-mass index measured as body weight (kg) divided by height (m) squared
Time Frame
Baseline and 3, 6, 9, 12 and 24 months
Title
Change in fasting insulin
Description
Circulating fasting insulin concentrations
Time Frame
Baseline and 3, 6, 9, 12 and 24 months
Title
Change in fasting C-peptide
Description
Circulating fasting C-peptide concentrations
Time Frame
Baseline and 3, 6, 9, 12 and 24 months
Title
Change in fasting TAG
Description
Circulating fasting triacylglycerol concentrations
Time Frame
Baseline and 3, 6, 9, 12 and 24 months
Title
Change in fasting HDL cholesterol
Description
Circulating fasting high-density lipoprotein cholesterol (HDL-C)
Time Frame
Baseline and 3, 6, 9, 12 and 24 months
Title
Change in TAG/HDL-C ratio
Description
The ratio of circulating fasting triacylglycerol (TAG) and high-density lipoprotein cholesterol (HDL-C)
Time Frame
Baseline and 3, 6, 9, 12 and 24 months
Title
Change in fasting LDL cholesterol
Description
Circulating fasting low-density lipoprotein cholesterol (LDL-C)
Time Frame
Baseline and 3, 6, 9, 12 and 24 months
Title
Change in apolipoprotein profile
Description
Circulating fasting apolipoprotein profile measured by multiplex ELISA
Time Frame
Baseline and 3, 6, 9, 12 and 24 months
Title
Change in circulating and urine metabolites associated with one-carbon metabolism
Description
Circulating metabolites in the serine, glycine and histidine pathways measured in the fasted state by GC-MS/MS
Time Frame
Baseline and 3, 6, 9, 12 and 24 months
Title
Change in total fat mass
Description
Total fat mass measured by bioimpedance analysis (BIA)
Time Frame
Baseline and 3, 6, 9, 12 and 24 months
Title
Change in lean mass
Description
Lean mass will be measured by bioimpedance analysis (BIA)
Time Frame
Baseline and 3, 6, 9, 12 and 24 months
Title
Change in appetite/fullness
Description
Subjective appetite and fullness assessed and quantified by the VAS questionnaire
Time Frame
Baseline and 3, 6, 9, 12 and 24 months
Title
Change in gastrointestinal symptoms by the Roma III questionnaire
Description
Gastrointestinal health will be surveyed and quantified by a questionnaire (Rome III Diagnostic Criteria for Irritable Bowel Syndrome (IBS)). The questionnaire surveys criteria for diagnosis of IBS within a 12-week period. The criteria for IBS are based on recurrent abdominal pain or discomfort, 3 days per month in the last 3 months (12 weeks), associated with ≥2 of the following criteria: 1.Improvement with defecation; 2. Onset associated with a change in stool frequency; 3. Onset associated with a change in stool form (appearance). The criteria are fulfilled with symptoms onset 6 months prior to diagnosis.
Time Frame
Baseline and 3, 6, 9, 12 and 24 months
Title
Change in gastrointestinal symptoms by the IBS-SSS questionnaire
Description
Gastrointestinal health will be surveyed by the IBS-SSS questionnaire. Scores on the IBS-SSS range from 0 to 500 with higher scores indicating more severe symptoms. Subjects can be categorized as having mild (75-175), moderate (175-300), or severe (>300) IBS. A decrease of 50 points is associated with a clinically meaningful improvement. Each question on the VAS ranges from 0-100mm, where higher score indicates more severe symptoms. The categorization based on scores (total possible score = 500) are as follows: 0-75 = not IBS 75-175= mild IBS 175-300 = moderate IBS 300-500 = severe IBS
Time Frame
Baseline and 3, 6, 9, 12 and 24 months
Title
Change in fatigue
Description
The Fatigue Impact Scale will be used to compute a total score for fatigue by summing up the scores for subclasses as follows: cognitive functioning (10 items, subscale range: 0-40), physical functioning (10 items, subscale range: 0-40), and psychosocial functioning (20 items, subscale range: 0-80). The statements are ranged on a five-level scale (0 = no problem to 4 = extreme problems), giving a maximum total FIS score of 160 (total scale range: 0-160) where low scores indicate less fatigue-related issues.
Time Frame
Baseline and 3, 6, 9, 12 and 24 months
Title
Change in perception of health / quality of life
Description
Obesity-specific quality of life is measured with "Patient-Reported Outcomes in Obesity" (PROS), which consists of 8 items tapping how different life domains are affected by obesity. PROS have one overall score, ranging from 0 (optimal) to 3 (poorest). Generic health-related quality of life is measured with RAND-36, which consists of dimensions ranging from 0 (poorest) to 100 (optimal). There are 8 subscales; physical functioning, physical role functioning, bodily pain, general health, vitality, social functioning, emotional role functioning and mental health. In addition, RAND-36 also have 2 summary scores: the physical component summary (PCS) (tapping from physical functioning, physical role functioning, bodily pain and general health) and mental component summary (MCS) (tapping from vitality, social functioning, emotional role functioning and mental health).
Time Frame
Baseline and 3, 6, 9, 12 and 24 months
Title
Change in quality of life related to gastrointestinal symptoms
Description
The SF-NDI (Short-Form Nepean Dyspepsia Index (SF-NDI)) questionnaire will be used to assess quality of life / psychological wellbeing related to gastrointestinal symptoms. The 10-item SF-NDI was constructed and validated in patients with functional gastrointestinal disorders for measuring health-related quality of life. The 10-item short form includes five subscales: tension, interference with daily activities, eating/drinking, knowledge/control, and work/study, and each subscale contains two items. The items were measured by a 5-point graded Likert scale from 1 to 5. A total sum score for quality of life and a sum score for each of the five subscales were calculated by adding up scores for each item (range of total quality of life, 10-50; range of each subscale, 2-10). Higher scores indicate worse functioning or symptoms.
Time Frame
Baseline and 3, 6, 9, 12 and 24 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Body-mass index (BMI) equal to or above 30 kg/m2 and/or waist circumference equal to or above 102 cm for men and 88 cm for women Weight stable during the last 2 months before start of the study (less than 5 % change in body weight up or down) No known diabetes or consumption of diabetes medication Desire to follow a specified dietary pattern using specific recipes throughout the time of the study period Ability to periodically record food intake using a specially designed app for the study Exclusion Criteria: Use of statins and/or diabetes medication Recent surgical or antibiotics treatment during the last 2 months before start of the study Chronic inflammatory bowel disease Serious disease Smoking Pregnancy or breast feeding Alcohol consumption during the study of more than 2 alcohol units per day (1 unit = 15 ml (12.8 g) pure alcohol)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Simon N Dankel, PhD
Organizational Affiliation
University of Bergen
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Gunnar Mellgren, MD PhD
Organizational Affiliation
Haukeland University Hospital
Official's Role
Study Director
Facility Information:
Facility Name
Forskningsenhet for helseundersøkelser (research unit for clinical trials), Department of Clinical Science, University of Bergen
City
Bergen
ZIP/Postal Code
5021
Country
Norway

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
36116147
Citation
Sommersten CH, Laupsa-Borge J, Andersen AIO, Fasmer KE, Holmefjord MA, Revheim I, Johannessen KK, Naesheim NT, Storas I, Leikanger T, Amundsen K, Skjerve KL, Lawrence-Archer L, Spjelkavik C, Haldorsen I, Lindseth I, Dierkes J, Mellgren G, Dankel SN. Diets differing in carbohydrate cellularity and amount similarly reduced visceral fat in people with obesity - a randomized controlled trial (CARBFUNC). Clin Nutr. 2022 Oct;41(10):2345-2355. doi: 10.1016/j.clnu.2022.08.028. Epub 2022 Sep 5.
Results Reference
derived

Learn more about this trial

Dietary Carbohydrate and Internal Body Fat

We'll reach out to this number within 24 hrs